查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298367

馬來酸氯苯那敏市場：按配方、按應用（過敏、花粉熱、感冒、流淚、喉嚨/皮膚瘙癢、過敏性休克、蕁麻疹）、按分銷渠道：2023年-2032年全球機會分析和行業預測

Chlorpheniramine Maleate Market By Dosage Form, By Application (Allergy, Hay Fever, Common Cold, Watery Eyes, Itchy Throat/Skin, Anaphylactic Shock, Urticaria), By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 438 Pages | 商品交期: 2-3個工作天內

價格

2022 年馬來酸氯苯那敏市場規模為 4.686 億美元，2023 年至 2032 年復合年增長率為 4.9%，預計 2032 年將達到 7.514 億美元。

馬來酸氯苯那敏市場-IMG1

撲爾敏是一種抗組胺藥，用於緩解過敏、花粉熱和普通感冒的症狀。 這些症狀包括皮疹、流淚、眼睛/鼻子/喉嚨/皮膚發癢、咳嗽、流鼻涕和打噴嚏。 這種藥物的作用是阻斷過敏反應過程中身體產生的某種天然物質（組胺）。 通過阻斷體內產生的另一種天然物質（乙□膽鹼），它可以使體液乾燥並緩解流淚和流鼻涕等症狀。

推動馬來酸氯苯那敏市場增長的主要因素是過敏和呼吸道疾病（例如過敏性鼻炎和蕁麻疹）患病率的上升。 例如，根據美國哮喘與過敏基金會 2021 年的一份報告，美國約有 8100 萬人被診斷患有季節性過敏性鼻炎（花粉症）。 這相當於約 26% 的成年人（6700 萬）和約 19% 的兒童（1400 萬）。 此外，製藥技術和給藥系統的進步導致馬來酸氯苯那敏新劑型的開發，例如緩釋片劑和液體劑型，其功效、便利性和患者依從性得到改善，導致預測市場預計將增長期間。

然而，消費者偏好的變化，例如轉向自然療法和整體治療方法、對其他類型藥物的偏好，以及馬來酸撲爾敏症狀（例如嗜睡、口乾、視力模糊和尿瀦留等潛在副作用）阻礙了市場增長。 相反，用於開發副作用更少、療效更高的新型療法的研發活動激增，預計將為預測期內的市場增長提供利潤豐厚的機會。

內容

第一章簡介

第 2 章執行摘要

第三章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資領域
  • 波特五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 協調員
      • 城市化進程和生活方式的變化
      • 過敏性疾病增加
      • 技術進步突飛猛進
    • 阻礙因素
      • 馬來酸氯苯那敏可能產生副作用
      • 更多地轉向替代藥物
    • 機會
      • 新興經濟體的高增長潛力
  • COVID-19 對市場的影響分析

第 4 章馬來酸氯苯那敏市場：按配方

  • 概述
    • 市場規模和預測
  • 藥丸
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 糖漿
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 眼藥水
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 5 章馬來酸氯苯那敏市場：按應用分類

  • 概述
    • 市場規模和預測
  • 過敏
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 花粉熱（過敏性鼻炎）
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 冷
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 淚眼汪汪
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 喉嚨/皮膚發癢
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 過敏性休克
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 蕁麻疹
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 6 章馬來酸氯苯那敏市場：按分銷渠道劃分

  • 概述
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 零售藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 網上藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 7 章馬來酸氯苯那敏市場：按地區

  • 概述
    • 市場規模和預測：按地區劃分
  • 北美
    • 主要趨勢和機遇
    • 市場規模和預測：按劑型劃分
    • 市場規模和預測：按應用分類
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模和預測：按劑型劃分
    • 市場規模和預測：按應用分類
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模和預測：按劑型劃分
    • 市場規模和預測：按應用分類
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 亞太地區其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模和預測：按劑型劃分
    • 市場規模和預測：按應用分類
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分
      • 其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按劑型劃分
      • 市場規模和預測：按應用分類
      • 市場規模和預測：按分銷渠道劃分

第 8 章競爭格局

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競賽儀表板
  • 比賽熱圖
  • 2022 年關鍵人物定位

第 9 章公司簡介

  • GlaxoSmithKline plc
  • Bayer AG
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Alkem Laboratories Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
  • Sun Pharmaceutical Industries Limited
  • Novalab Healthcare Pvt. Ltd.
  • Capellon Pharmaceuticals
Product Code: A03630

The chlorpheniramine maleate market size was valued at $468.6 million in 2022, and is projected to reach $751.4 million by 2032, growing at a CAGR of 4.9% from 2023 to 2032.

Chlorpheniramine Maleate Market - IMG1

Chlorpheniramine is an antihistamine used to relieve symptoms of allergy, hay fever, and the common cold. These symptoms include rashes, watery eyes, itchy eyes/nose/throat/skin, cough, runny nose, and sneezing. This medication works by blocking a certain natural substance (histamine) that the body makes during an allergic reaction. By blocking another natural substance made by the body (acetylcholine), it helps dry up some body fluids to relieve symptoms such as watery eyes and runny nose.

The key factor that drives the growth of the chlorpheniramine maleate market is the rise in prevalence of allergies and related respiratory conditions such as allergic rhinitis, and hives. For instance, according to report published by Asthma & Allergy Foundation of America in 2021, approximately 81 million people in the U.S. were diagnosed with seasonal allergic rhinitis (hay fever). This equals around 26% (67 million) of adults and 19% (14 million) of children. Furthermore, advances in pharmaceutical technology and drug delivery systems have resulted in the development of new formulations of chlorpheniramine maleate, such as extended-release tablets or liquid formulations, which offer improved efficacy, convenience, and patient compliance that are expected to drive the growth of the market during the forecast period.

However, changes in consumer preferences, such as a shift towards natural remedies, holistic approaches, or preferences for other types of medications, and potential adverse effects of chlorpheniramine maleate, such as drowsiness, dry mouth, blurred vision, and urinary retention hamper market growth. Conversely, a surge in R&D activities for the development of novel therapies with fewer side effects and greater efficacy is expected to provide lucrative opportunities for the growth of the market during the forecast period.

The chlorpheniramine maleate market is segmented into dosage form, application, end user, and region. By dosage form, the market is classified into tablets, syrup, and eye drops. On the basis of application, it is fragmented into allergy, hay fever (allergic rhinitis), common cold, watery eyes, itchy throat/skin, anaphylactic shock, and urticaria. By distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America garnered the maximum share of the chlorpheniramine maleate market in 2022 and is anticipated to remain dominant during the forecast period. This is attributed to an increase in prevalence of allergic conditions, a growth in geriatric population as adults may have a higher risk of developing allergies and high healthcare expenditure on drugs used to treat allergic conditions such as hay fever, the common cold, anaphylactic shock, and others. Furthermore, a surge in awareness among the population about the symptoms and management of allergies and advancements in healthcare infrastructure are expected to fuel the market growth.

Asia-Pacific is expected to register the fastest CAGR during the forecast period owing to an increase in incidence of allergic conditions and a surge in population and urbanization. Furthermore, growth in healthcare infrastructure and surge in R&D activities by key market players for the development of new drugs to treat allergic disorders such as allergic rhinitis, urticaria, and hay fever boost the growth of the market.

The key players that operate in the chlorpheniramine maleate market are: Alkeem Laboratories Ltd., Bayer AG, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novalab Healthcare Pvt. Ltd., Capellon Pharmaceuticals, Sun Pharmaceutical Industries Limited, Viatris Inc., and Zydus Lifesciences Limited.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chlorpheniramine maleate market analysis from 2022 to 2032 to identify the prevailing chlorpheniramine maleate market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the chlorpheniramine maleate market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global chlorpheniramine maleate market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Dosage Form

  • Syrup
  • Eye Drops
  • Tablets

By Application

  • Allergy
  • Hay Fever (Allergic Rhinitis)
  • Common Cold
  • Watery Eyes
  • Itchy Throat/Skin
  • Anaphylactic Shock
  • Urticaria

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

  • Alkem Laboratories Ltd.
  • Bayer AG
  • Capellon Pharmaceuticals
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novalab Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Viatris Inc.
  • Zydus Lifesciences Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in urbanization and change in lifestyles
      • 3.4.1.2. Increase in the prevalence of allergic conditions
      • 3.4.1.3. Surge in technological advancement
    • 3.4.2. Restraints
      • 3.4.2.1. Potential side effects of chlorpheniramine maleate
      • 3.4.2.2. Increase in shift towards alternative medicines
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in developing economies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Tablets
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Syrup
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Eye Drops
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Allergy
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Hay Fever (Allergic Rhinitis)
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Common Cold
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Watery Eyes
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Itchy Throat/Skin
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Anaphylactic Shock
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country
  • 5.8. Urticaria
    • 5.8.1. Key market trends, growth factors and opportunities
    • 5.8.2. Market size and forecast, by region
    • 5.8.3. Market share analysis by country

CHAPTER 6: CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: CHLORPHENIRAMINE MALEATE MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Dosage Form
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Dosage Form
      • 7.2.5.1.3. Market size and forecast, by Application
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Dosage Form
      • 7.2.5.2.3. Market size and forecast, by Application
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Dosage Form
      • 7.2.5.3.3. Market size and forecast, by Application
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Dosage Form
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Dosage Form
      • 7.3.5.1.3. Market size and forecast, by Application
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Dosage Form
      • 7.3.5.2.3. Market size and forecast, by Application
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Dosage Form
      • 7.3.5.3.3. Market size and forecast, by Application
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Dosage Form
      • 7.3.5.4.3. Market size and forecast, by Application
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Dosage Form
      • 7.3.5.5.3. Market size and forecast, by Application
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Dosage Form
      • 7.3.5.6.3. Market size and forecast, by Application
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Dosage Form
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Dosage Form
      • 7.4.5.1.3. Market size and forecast, by Application
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Dosage Form
      • 7.4.5.2.3. Market size and forecast, by Application
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Dosage Form
      • 7.4.5.3.3. Market size and forecast, by Application
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Dosage Form
      • 7.4.5.4.3. Market size and forecast, by Application
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Dosage Form
      • 7.4.5.5.3. Market size and forecast, by Application
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Dosage Form
      • 7.4.5.6.3. Market size and forecast, by Application
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Dosage Form
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Dosage Form
      • 7.5.5.1.3. Market size and forecast, by Application
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Dosage Form
      • 7.5.5.2.3. Market size and forecast, by Application
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Dosage Form
      • 7.5.5.3.3. Market size and forecast, by Application
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Dosage Form
      • 7.5.5.4.3. Market size and forecast, by Application
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. GlaxoSmithKline plc
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Bayer AG
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Merck & Co., Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Johnson & Johnson
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Alkem Laboratories Ltd.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Viatris Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Zydus Lifesciences Limited
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Sun Pharmaceutical Industries Limited
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Novalab Healthcare Pvt. Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
  • 9.10. Capellon Pharmaceuticals
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 02. CHLORPHENIRAMINE MALEATE MARKET FOR TABLETS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. CHLORPHENIRAMINE MALEATE MARKET FOR SYRUP, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. CHLORPHENIRAMINE MALEATE MARKET FOR EYE DROPS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 06. CHLORPHENIRAMINE MALEATE MARKET FOR ALLERGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. CHLORPHENIRAMINE MALEATE MARKET FOR HAY FEVER (ALLERGIC RHINITIS), BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. CHLORPHENIRAMINE MALEATE MARKET FOR COMMON COLD, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. CHLORPHENIRAMINE MALEATE MARKET FOR WATERY EYES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. CHLORPHENIRAMINE MALEATE MARKET FOR ITCHY THROAT/SKIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. CHLORPHENIRAMINE MALEATE MARKET FOR ANAPHYLACTIC SHOCK, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. CHLORPHENIRAMINE MALEATE MARKET FOR URTICARIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 14. CHLORPHENIRAMINE MALEATE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. CHLORPHENIRAMINE MALEATE MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. CHLORPHENIRAMINE MALEATE MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. CHLORPHENIRAMINE MALEATE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 22. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 23. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 26. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. UK CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 42. UK CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. UK CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 45. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 61. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 67. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 74. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 80. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 81. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 83. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 84. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 89. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 90. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 92. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 93. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 94. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 95. BAYER AG: KEY EXECUTIVES
  • TABLE 96. BAYER AG: COMPANY SNAPSHOT
  • TABLE 97. BAYER AG: PRODUCT SEGMENTS
  • TABLE 98. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 99. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 100. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 101. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 102. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 103. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 104. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 105. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 106. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 107. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 108. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 109. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 110. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 111. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 112. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 113. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 114. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 115. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 116. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 117. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 118. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 121. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 122. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 123. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • TABLE 124. NOVALAB HEALTHCARE PVT. LTD.: KEY EXECUTIVES
  • TABLE 125. NOVALAB HEALTHCARE PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 126. NOVALAB HEALTHCARE PVT. LTD.: PRODUCT SEGMENTS
  • TABLE 127. NOVALAB HEALTHCARE PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 128. CAPELLON PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 129. CAPELLON PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 130. CAPELLON PHARMACEUTICALS: PRODUCT SEGMENTS
  • TABLE 131. CAPELLON PHARMACEUTICALS: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. CHLORPHENIRAMINE MALEATE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF CHLORPHENIRAMINE MALEATE MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN CHLORPHENIRAMINE MALEATE MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCHLORPHENIRAMINE MALEATE MARKET
  • FIGURE 10. CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR TABLETS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR SYRUP, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR EYE DROPS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR ALLERGY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR HAY FEVER (ALLERGIC RHINITIS), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR COMMON COLD, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR WATERY EYES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR ITCHY THROAT/SKIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR ANAPHYLACTIC SHOCK, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR URTICARIA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF CHLORPHENIRAMINE MALEATE MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. CHLORPHENIRAMINE MALEATE MARKET BY REGION, 2022
  • FIGURE 27. U.S. CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. CANADA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. MEXICO CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. GERMANY CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. FRANCE CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. UK CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. ITALY CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SPAIN CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. JAPAN CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. CHINA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. INDIA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50. COMPETITIVE DASHBOARD
  • FIGURE 51. COMPETITIVE HEATMAP: CHLORPHENIRAMINE MALEATE MARKET
  • FIGURE 52. TOP PLAYER POSITIONING, 2022
  • FIGURE 53. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. MERCK & CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 70. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 73. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)